medigraphic.com

2018, Número S1

<< Anterior Siguiente >>

Rev Med Inst Mex Seguro Soc 2018; 56 (S1)


Prescripción inapropiada en adultos mayores: revisión de la literatura y alertas de seguridad

Mino-León D, Galván-Plata ME, Anda-Garay JC, Noyola-García ME, Cooper D

Idioma: Español
Referencias bibliográficas: 52
Paginas: 71-81
Archivo PDF: 339.75 Kb.


RESUMEN

Introducción: los errores de prescripción son un factor de riesgo para que los pacientes presenten eventos adversos; una estrategia que se ha incorporado a la atención médica para disminuirlos es el uso de herramientas informáticas. El objetivo fue obtener el fundamento científico que sustente la elaboración de alertas de errores de prescripción para cuatro padecimientos de mayor prevalencia en población ≥ 65 años.
Métodos: se revisó la literatura del 2010 al 2015 para obtener información de eventos adversos o reacciones ligadas al uso de fármacos empleados en diabetes mellitus (DM), hipertensión arterial sistémica (HAS), enfermedad osteoarticular (EO) y depresión; la revisión incluyó las bases de datos PubMed, OVID, Cochrane Library, LILACS, MEDES, Portal Mayores y SIETES. Se integró un grupo de médicos que analizaron los artículos y elaboraron las alertas de los medicamentos involucrados en los tratamientos de las enfermedades incluidas.
Resultados: se obtuvieron 76 artículos in extenso, de los cuales 47 fueron analizados por el grupo de médicos, quienes eliminaron 18 artículos. De los 29 restantes, se integraron 55 alertas: 5 de DM, 16 de HAS, 15 de EO y 19 de depresión.
Conclusión: las alertas principalmente fueron interacciones fármaco-fármaco confirmadas y reacciones adversas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Laing R, Hogerzeil H, Ross-Degnan D. Ten recommendations to improve use of medicines in developing countries. Health Policy Plan. 2001;16(1):13-20.

  2. Organización Mundial de la Salud (OMS). Uso racional de medicamentos. Informe de la conferencia de expertos, Nairobi, 1985. Ginebra: OMS; 1986. Disponible en http://apps.who.int/medicinedocs/es/m/ abstract/Js21286es/ [Consultado el 13 de febrero de 2016].

  3. Promoting rational drug use Course (Draft). International Network for Rational Use of Drugs (INRUD); 1996.

  4. Ramos G, Olivares G. Uso racional de medicamentos: una tarea de todos. Santiago de Chile: Departamento de Políticas Farmacéuticas y Profesiones Médicas, División de Políticas Públicas Saludables y Promoción, Gobierno de Chile; 2010. Disponible en: http://docplayer.es/46731-Usoracional- de-medicamentos-una-tarea-de-todos. html [Consultado el 13 de febrero de 2016].

  5. Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282(3):267-70.

  6. Ellis SL, Carter BL, Malone DC, Billups SJ, Okano GJ, Valuck RJ, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: The IMPROVE study. Pharmacotherapy. 2000;20(12):1508-16.

  7. Weingart S, Simchowitz B, Padolsky H, Isaac T, Serger A, Massagli M, et al. An empirical model to estimate the potential impact of medication safety alerts on patient safety, health care utilization, and cost in ambulatory care. Arch Intern Med. 2009;169 (16):1465-73.

  8. Peral-Aguirregoitia P, Lertxundi-Etxebarria U, Martínez-Bengoechea MJ, Mora-Atorrasagasti O, Franco-Lamela E, Gabilondo-Zelaia I. Evaluación prospectiva de interacciones entre medicamentos en pacientes ingresados mediante una aplicación informática. Farm Hosp. 2007;31(2):93-100.

  9. Weingart S, Toth M, Sands D, Aronson M, Davis R, Phillips R. Physicians’ decisions to override computarized drug alerts in primary care. Arch Intern Med. 2003;163(21):2625-31.

  10. Isaac T, Weissman J, Davis R, Massagli M, Cyrulik A, Sands D, et al. Overrides of medication alerts in ambulatory care. Arch Intern Med. 2009;169(3):305-11.

  11. Monane M, Matthias DM, Nagle BA, Kelly MA. Improving prescribing patterns for the elderly through an online drug utilization review intervention: a system linking the physician, pharmacist and computer. JAMA. 1998;280(14):1249-52.

  12. Shah N, Seger A, Seger D, Fiskio J, Kuperman G, Blumenfeld B, et al. Improving Acceptance of Computerized Prescribing Alerts in Ambulatory Care. J Am Med Inform Assoc. 2006;13(1):5-11.

  13. Consejo Nacional de Población (CONAPO). Índices demográficos para adultos mayores. http://www.conapo. gob.mx/es/CONAPO/Aspectos_Generales_de_los_ resultados_de_las_Proyecciones_de_Poblacion

  14. World Health Organization (WHO). Active aging: a policy framework. Geneva: WHO; 2002.

  15. Hinojosa-Amaya JM, Rodríguez-García FG, Yeverino- Castro SG, Sánchez-Cárdenas M, Villarreal- Alarcón MÁ, Galarza-Delgado DÁ. Medication errors: electronic vs. paper-based prescribing. Experience at a tertiary care university hospital. J Eval Clin Pract. 2016;22(5):751-4.

  16. Luna-Medina MA, Peralta-Pedrero ML, Pineda- Aquino V, Durán-Fernández YC, Avalos-Mejía A, Aguirre-García Mdel C. Inappropriate prescribing in older adults with chronic-degenerative disease. Rev Med Inst Mex Seguro Soc. 2013;51(2):142-9.

  17. Manitpisitkul P, Curtin, Shalayda K, Wang S, Ford L, Heald DL. Open-Label Drug–Drug Interaction Study of the Steady-State Pharmacokinetics of Topiramate and Glyburide in Patients with Type 2 Diabetes Mellitus. Clin Drug Investig. 2013;33(12):929-38.

  18. Tan A, Holmes HM, Kuo YF, Raji MA, Goodwin JS. Co-administration of Co-trimoxazole with Sulfonylureas: Hypoglycemia Events and Pattern of Use. J Gerontol A Biol Sci Med Sci. 2015;70(2):247-54.

  19. Parekh TM, Raji M, Lin YL, Tan A, Kuo YF, Goodwin JS. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. JAMA Intern Med. 2014;174(10):1605-12.

  20. Shankar RR, Xu L, Golm GT, O’Neill EA, Goldstein BJ, Kaufman KD, et al. A comparison of glycaemic effects of sitagliptin and sulfonylureas in elderly patients with type 2 diabetes mellitus. Int J Clin Pract. 2015;69(6):626-31.

  21. Ellis JJ, Sadosky AB, Eyck LLT, Mudumby P, Cappelleri JC, Ndehi L, et al. A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine. BMC Health Serv Res. 2015;15:159. doi: 10.1186/s12913-015-0829-9.

  22. Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain Safety Announcement. USA: FDA; 08/28/2015. Disponible en http://www.fda.gov/Drugs/DrugSafety/ ucm459579.htm

  23. Obreli-Neto PR, Nobili A, de Oliveira-Baldoni A, Guidoni CM, de Lyra-Júnior DP, Pilger D, et al. Adverse drug reactions caused by drug-drug interactions in elderly outpatients: a prospective cohort study. Eur J Clin Pharmacol. 2012;68(12):1667-76.

  24. Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA review of cardiovascular risks for diabetics taking hypertension drug olmesartan not conclusive; label updates required. USA: FDA; 24/06/2014. Disponible en https://www. fda.gov/Drugs/DrugSafety/ucm402323.htm

  25. Settergren J, Eiermann B, Mannheimer B. Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy- -a nationwide register study. PLoS One. 2013;8(8): e69545.

  26. Ho CK, Walker SW. Statins and their interactions with other lipid-modifying medications: safety issues in the elderly. Ther Adv Drug Saf. 2012 Feb;3(1):35- 46. 27. Wright AJ, Gomes T, Mamdani MM, Horn JR, Juurlink DN. The risk of hypotension following co-prescription of macrolide antibiotics and calciumchannel blockers. CMAJ. 2011;183(3):303-7.

  27. Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, et al. Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA. 2013;310(23):2544-53.

  28. Kristensen KE, Zhu HJ, Wang X, Gislason GH, Torp- Pedersen C, Rasmussen HB, et al. Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study. Clin Pharmacol Ther. 2014;96(6):713-22.

  29. Fralick M, Macdonald EM, Gomes T, Antoniou T, Hollands S, Mamdani MM, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ. 2014;349:g6196. doi: 10.1136/bmj.g6196

  30. Antoniou T, Gomes T, Mamdani MM, Yao Z, Hellings C, Garg AX, et al. Trimethoprim-sulfamethoxazole induced hyperkalaemia in elderly patients receiving spironolactone: nested case-control study. BMJ. 2011; 343:d5228. doi: 10.1136/bmj.d5228

  31. Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 2011;9(6):364-77.

  32. Fournier JP, Sommet A, Bourrel R, Oustric S, Pathak A, Lapeyre-Mestre M, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study. Eur J Clin Pharmacol. 2012;68(11):1533-40.

  33. Moore N, Pollack C, Butkerait P. Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Ther Clin Risk Manag. 2015;11:1061-75.

  34. Danelich IM, Wright SS, Lose JM, Tefft BJ, Cicci JD, Reed BN. Safety of nonsteroidal antiinflammatory Drugs in patients with cardiovascular disease. Pharmacotherapy. 2015;35(5):520-35.

  35. Fundació Institut Català de Farmacologia. Riesgos de los AINE en pacientes que reciben tratamiento antitrombótico. Butlletí Groc. 2015;28(2):5-10. https://ddd. uab.cat/pub/butgroc/butgrocSPA/butgroc_a2015m4- 6v28n2iSPA.pdf

  36. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM; SUCCESS VI Study Group. Cyclooxygenase- 2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther. 2001;8(2):85-95.

  37. Food and Drug Administration (FDA). FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. Safety Announcement. USA: FDA; 07/09/2015. Disponible en https://www.fda.gov/downloads/Drugs/ DrugSafety/UCM453941.pdf

  38. Patanè M, Ciriaco M, Chimirri S, Ursini F, Naty S, Grembiale RD, et al. Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis. Adv Pharmacol Sci. 2013; 2013:313858. doi: 10.1155/2013/313858.

  39. Schelleman H, Brensinger CM, Bilker WB, Hennessy S. Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a casecontrol study. PLoS ONE. 2011; 6(6): e21447. doi: 10.1371/journal.pone.0021447

  40. Yeung CK, Fujioka Y, Hachad H, Levy RH, Isoherranen N. Are Circulating metabolites important in drug-drug interactions? Quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther. 2011;89(1):105-13.

  41. Bell JS, Heidi T, Taipale HT, Soini H, Pitkälä KH. Concomitant use of SSRIs, NSAIDs/Aspirin and gastroprotective drugs among residents of long-term care facilities. Clin Drug Investig. 2011;31(5):338-42.

  42. Chen G, Lee R, Højer AM, Buchbjerg JK, Serenko M, Zhao Z. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727-36.

  43. Park SH, Wackernah RC, Stimmel GL. Serotonin syndrome: Is it a reason to avoid the use of tramadol with antidepressants. J Pharm Pract. 2014;27(1):71-8.

  44. Montastruc F, Sommet A, Bondon-Guitton E, Durrieu G, Bui E, Bagheri H, et al. The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur J Clin Pharmacol. 2012;68(5):767-75.

  45. Spinewine A, Schmader KE, Barber N, Hughes C, Lapane KL, Swine C et al. Appropriate prescribing in elderly people: how well can it be measure and optimized? Lancet. 2007;370(9582):173-84.

  46. Guiding Principles for the Care of Older Adults with Multimorbidity: An Approach for Clinicians American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity. J Am Geriatr Soc. 2012;60(10):1957-68.

  47. Fortin M, Lapointe L, Hudon C, Vanasse A, Ntetu AL, Maltais D. Multimorbidity and quality of life in primary care: a systematic review. Health Qual Life Outcomes. 2004,2:51-62.

  48. Townsend A, Hunt K, Wyke S. Managing multiple morbidity in mid-life: a qualitative study of attitudes to drug use. BMJ. 2003;327(7419):837-42.

  49. Mino-León D, Reyes-Morales H, Galván-Plata ME, Ponce-Monter H, Palma JA, Amato D et al. Drug treatment of hypertension: compliance and adverse reactions in a cohort of hypertensive patients in a primary care setting. Rev Invest Clin. 2007;59(1):8-14.

  50. Castro-Ríos A, Reyes-Morales H, Pérez-Cuevas R. An evaluation of a continuing medical education program for primary care services in the prescription of hypoglycemic agents in diabetes mellitus type 2. Salud Publica Mex. 2008;50(suppl 4):s445-52.

  51. Mino-León D, Reyes-Morales H, Jasso L, Doubova SV. Physicians and pharmacists: collaboration to improve the quality of prescriptions in primary care in Mexico. Int J Clin Pharm. 2012;34(3):475-80.

  52. Mino-León D, Galván-Plata ME, Doubova SV, Flores- Hernández S, Reyes-Morales H. Estudio farmacoepidemiológico de potenciales interacciones farmacológicas y sus determinantes, en pacientes hospitalizados. Rev Invest Clin. 2011;63(2):932-54.




2020     |     www.medigraphic.com